Evidence map›Paper›PMID 42433623›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026

Where antibiotic time-outs work: department- and ward-stratified effects of a pharmacist-led anti-MRSA time-out.

Risako Yamamoto, Yasuaki Tagashira, Do Dang An, Yui Enatsu, Maya Satake, Yoshibumi Aiso, Yoshiaki Gu

Abstract read
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Risako YamamotoDepartment of Pharmacy, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.ORCID https://orcid.org/0009-0008-7490-5642
Yasuaki TagashiraDepartment of Infection Control, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3736-4046
Do Dang AnInstitute of Science Tokyo Graduate School of Medical and Dental Sciences, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4373-8462
Yui EnatsuDepartment of Pharmacy, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.
Maya SatakeDepartment of Pharmacy, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.
Yoshibumi AisoDepartment of Pharmacy, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.
Yoshiaki GuDepartment of Infection Control, Institute of Science Tokyo Hospital, Bunkyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2509-1052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the impact of a pharmacist-led anti-methicillin-resistant Design: Single-center before-after interrupted time-series study. Setting: An 813-bed tertiary hospital in Tokyo, Japan. Patients: Inpatients receiving intravenous anti-MRSA agents. Methods: Stewardship pharmacists alerted physicians to reassess intravenous anti-MRSA therapy at 72 hours after its start. Monthly days of therapy per 1,000 patient-days (DOT) were compared between October 2017 to September 2022 and October 2022 to September 2024 after stratification by ward and department. Acceptance rate and therapeutic drug monitoring (TDM) tests were also assessed. Results: Hospital-wide DOT showed an immediate non-significant decrease (-19.23; 95% confidence interval [CI] -59.17 to 20.72; Conclusions: Targeting an implementation to areas most likely to benefit from it may improve antimicrobial stewardship when resources are limited. Complementary strategies may be needed if acceptance is poor.

Identifiers

PMID42433623
PMCPMC13352333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.